PE-Backed IBA Molecular Pays $690M For Nuclear Imaging Biz
Private equity-backed radiopharmaceuticals products maker IBA Molecular has agreed to buy the nuclear imaging business of Irish drugmaker Mallinckrodt PLC in a deal worth $690 million, the companies said on Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article